This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Gordon C. Sauer, MD
Kansas City, Mo

JAMA. 1971;217(8):1105-1106.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Several aspects of the SPECIAL COMMUNICATION on "Drug Combinations: A Critique of Proposed New Federal Regulations," by F. Gilbert McMahon, MD, deserve comment, especially the statement at the end of the article (216:1008, 1971) that regulations involving clinicians ought to be made with the advice of clinicians and not simply with that of armchair MDs on blue-ribbon committees.

As a member of one of the three dermatology Panels of the Food and Drug Administration—Drug Efficacy Study, not only do I take exception to his statement about "armchair" MDs, but I really wonder where he got the information.

The inference that private practitioners were not involved in the judgements regarding these hundreds of drugs studied by the Drug Efficacy Study would be refuted by a careful study of the committee members and their positions. The accurate way to determine the exact amount of time that each one . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?